AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
+0.13 (0.73%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.33 - 18.13
52 week 16.49 - 28.42
Open 17.67
Vol / Avg. 324,142.00/536,878.00
Mkt cap 389.78M
P/E     -
Div/yield     -
EPS -0.44
Shares 21.80M
Beta 0.24
Inst. own 105%
May 22, 2014
AMAG Pharmaceuticals, Inc. Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 21, 2014
Q1 2014 AMAG Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Apr 9, 2014
AMAG Pharmaceuticals, Inc. at Needham Healthcare Conference - Webcast
Mar 3, 2014
AMAG Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 12, 2014
AMAG Pharmaceuticals, Inc. at Leerink Swann Global Healthcare Conference - Webcast
Feb 6, 2014
Q4 2013 AMAG Pharmaceuticals, Inc. Earnings Release
Feb 6, 2014
Q4 2013 AMAG Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Jan 22, 2014
AMAG Pharmaceuticals, Inc. to host Corporate Conference Call to provide a regulatory update - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -16.83% -11.88%
Operating margin -18.40% -14.37%
EBITD margin - -9.22%
Return on average assets -5.53% -3.67%
Return on average equity -8.46% -5.56%
Employees 148 -
CDP Score - -


1100 Winter Street
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turns, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. Its principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). It markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD.

Officers and directors

Michael A. Narachi Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Gino Santini Chairman of the Board
Bio & Compensation  - Reuters
William K. Heiden President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Scott A. Holmes Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller, Treasurer
Age: 38
Bio & Compensation  - Reuters
Frank E. Thomas Chief Operating Officer, Executive Vice President
Age: 43
Bio & Compensation  - Reuters
Gregory P. Madison Executive Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Scott B. Townsend Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Elizabeth Bolgiano Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Bio & Compensation  - Reuters